Citations

Institution: Mayo Clinic Clear

Showing 10 of 108104 citations.

Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial
Schneider, Bryan P. , Radovich, Milan , Vance, Gail H. , Li, Lang , Cobleigh, Melody , Perez, Edith A. , Shenkier, Tamara N., Nielsen, Kirsten Vang , Müller, Sven , Thor, Ann D. , Sparano, Joseph A. , Davidson, Nancy E. , Gray, Robert J. , Shen, Fei , Jiang, Guanglong , Miller, Kathy D. , Gralow, Julie R. , Dickler, Maura N. , Sledge, George W. , Badve, Sunil , Sparano, Joseph A

Clinical Cancer Research | January 23, 2013 | Volume: 19 | Issue: 5 | Pages: 1281-1289

10.1158/1078-0432.ccr-12-3029 | PMID 23340303 Get It

Abstract Purpose: Clinically validated biomarkers for anti-angiogenesis agents are not available. We have previously reported associations between candidate VEGFA single-nucleotide polymorphisms (SNP) and overall survival (OS) in E2100. The associations between tumor VEGFA amplification and outcome are evaluated here. Experimental Design: E2100 was a phase III trial comparing paclitaxel with or without bevacizumab for patients with metastatic breast cancer. FISH to assess gene amplification status for VEGFA was conducted on paraffin-embedded tumors from 363 patients in E2100. Evaluation for association between amplification status and outcomes was conducted. Results: Estrogen receptor (ER)+ or progesterone receptor (PR)+ tumors were less likely to have VEGFA amplification than ER/PR− tumors (P = 0.020). VEGFA amplification was associated with worse OS (20.2 vs. 25.3 months; P = 0.013) in univariate analysis with a trend for worse OS in multivariate analysis (P = 0.08). There was a significant interaction between VEGFA amplification, hormone receptor status, and study arm. Patients with VEGFA amplification and triple-negative breast cancers (TNBC) or HER2 amplification had inferior OS (P = 0.047); amplification did not affect OS for those who were ER+ or PR+ and HER2−. Those who received bevacizumab with VEGFA amplification had inferior progression-free survival (PFS; P = 0.010) and OS (P = 0.042); no association was seen in the control arm. Test for interaction between study arm and VEGFA amplification with OS was not significant. Conclusion: VEGFA amplification in univariate analysis was associated with poor outcomes; this was particularly prominent in HER2+ or TNBCs. Additional studies are necessary to confirm the trend for poor OS seen on multivariate analysis for patients treated with bevacizumab. Clin Cancer Res; 19(5); 1281–9. ©2012 AACR.
Predictors of Recurrent Instability After Acute Patellofemoral Dislocation in Pediatric and Adolescent Patients
Lewallen, Laura, McIntosh, Amy L. , Dahm, Diane L.

The American Journal of Sports Medicine | January 23, 2013 | Volume: 41 | Issue: 3 | Pages: 575-581

10.1177/0363546512472873 | PMID 23339838 Get It

Background: Patellofemoral instability is common in the pediatric and adolescent population, yet prognosis after the first dislocation has been difficult to determine. Purpose: To describe the demographics of pediatric and adolescent patients with a first-time patellofemoral dislocation and to determine predictors of recurrent instability. Study Design: Case-control study; Level of evidence, 3. Methods: A search of the Mayo Medical Index database between 1998 to 2010 was performed, and 2039 patients were identified. Inclusion criteria were (1) age 18 years or younger, (2) no history of patellofemoral subluxation/dislocation of the affected knee, (3) radiographs within 4 weeks of the initial instability episode, and (4) a dislocated patella requiring reduction or convincing history/findings suggestive of acute patellar dislocation (effusion/hemarthrosis, tenderness along medial parapatellar structures, and apprehension with lateral patellar translation). Radiographs were evaluated for trochlear dysplasia (Dejour classification) and patella alta (Caton-Deschamps and Insall-Salvati indices). Skeletal maturity was graded based on the distal femoral and proximal tibial physes (open, closing, or closed). Results: A total of 222 knees (120 male [54.1%] and 102 female [45.9%]) in 210 patients with an average age of 14.9 years (range, 9-18 years), met the inclusion criteria. Twenty-four patients (10.8%) underwent early surgery. All others were initially treated nonoperatively. Of the 198 patients in this group, 76 (38.4%) had recurrent instability, and 39 (51.3%) of these required surgical treatment. Recurrent instability was associated with trochlear dysplasia ( P < .01). Patients with both immature physes and trochlear dysplasia had a recurrence rate of 69% (33/48), with a hazard ratio of 3.3. Age, sex, body mass index, and patella alta were not statistically associated with recurrent instability. Conclusion: Nonoperative treatment for first-time patellofemoral dislocation resulted in a 62% success rate. However, skeletally immature patients with trochlear dysplasia had only a 31% success rate with nonoperative management. Nearly half of patients with recurrent instability required surgical intervention to gain stability.
Overall and Cancer-Specific Survival of Patients With Breast, Colon, Kidney, and Lung Cancers With and Without Chronic Lymphocytic Leukemia: A SEER Population-Based Study
Solomon, Benjamin , Rabe, Kari G. , Brewer, Jerry D., Cerhan, James R. , Slager, Susan L. , Shanafelt, Tait D. , Chaffee, Kari G. , Cerhan, James R

Journal of Clinical Oncology | January 23, 2013 | Volume: 31 | Issue: 7 | Pages: 930-937

10.1200/jco.2012.43.4449 | PMID 23341508 Get It

Purpose Chronic lymphocytic leukemia (CLL) is associated with an increased risk of developing second cancers. However, it is unknown whether CLL alters the disease course of these cancers once they occur. Patients and Methods All patients with cancers of the breast (n = 579,164), colorectum (n = 412,366), prostate (n = 631,616), lung (n = 489,053), kidney (n = 95,795), pancreas (n = 82,116), and ovary (n = 61,937) reported to the SEER program from 1990 to 2007 were identified. Overall survival (OS; death resulting from any cause) and cancer-specific survival were examined, comparing patients with and without pre-existing CLL. Cancer-specific survival was evaluated for each tumor type in a site-specific manner (eg, death resulting from breast cancer in a patient with breast cancer). Results Patients with cancers of the breast (hazard ratio [HR], 1.70; P < .001), colorectum (HR, 1.65; P < .001), kidney (HR, 1.54; P < .001), prostate (HR, 1.92; P < .001), or lung (HR, 1.19; P < .001) had inferior OS if they had a pre-existing diagnosis of CLL after adjusting for age, sex, race, and disease stage. These results for OS remained significant for patients with cancers of the breast, colorectum, and prostate after excluding or censoring CLL-related deaths. Cancer-specific survival was also inferior for patients with cancers of the breast (HR, 1.41; P = .005) and colorectum (HR, 1.46; P < .001) who had pre-existing CLL after adjusting for age, sex, race, and disease stage. Conclusion Inferior OS and cancer-specific survival was observed for several common cancers in patients with pre-existing CLL. Additional studies are needed to determine the optimal management of these malignancies in patients with CLL and whether more aggressive screening or alternative approaches to adjuvant therapy are needed.
Commentary: larazotide acetate ‐ an exciting new development for coeliac patients? Authors’ reply
Kelly, Ciarán P. , Green, P. H. R., DiMarino, Anthony J., Colatrella, Anthony M., Leffler, Daniel A. , Alexander, T. , Arsenescu, Razvan, Jiang, John , Arterburn, L. A., Paterson, Blake, Fedorak, Richard N. , Group, for the Larazotide Acetate Celiac Disease Study, Murray, Joseph A. , León, Francisco , Group, for the Larazotide Acetate Celiac Disease Study, Fedorak, R N

Alimentary Pharmacology & Therapeutics | January 22, 2013 | Volume: 37 | Issue: 4 | Pages: 496-497

10.1111/apt.12196 | PMID 23336684 Get It

Hemorrhagic cystic lesion of the median nerve: An unusual complication of venipuncture
Spinner, Robert J. , Edwards, William D. , Amrami, Kimberly K.

Clinical Anatomy | January 22, 2013 | Volume: 26 | Issue: 5 | Pages: 540-543

10.1002/ca.22197 | PMID 23338966 Get It

Faculty Opinions recommendation of Effect of mosapride combined with esomeprazole improves esophageal peristaltic function in patients with gastroesophageal reflux disease: a study using high resolution manometry.
Katzka, David A.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | January 21, 2013 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.717962062.793468755 Get It

Faculty Opinions recommendation of Interventions for dysphagia and nutritional support in acute and subacute stroke.
Katzka, David A.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | January 21, 2013 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.717962277.793468753 Get It

Faculty Opinions recommendation of Interventions for oropharyngeal dysphagia in children with neurological impairment.
Katzka, David A.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | January 21, 2013 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.717962207.793468752 Get It

Faculty Opinions recommendation of Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.
Katzka, David A.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | January 21, 2013 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.717962508.793468756 Get It

Faculty Opinions recommendation of Prevalence of gastro-esophageal reflux-type symptoms in individuals with irritable bowel syndrome in the community: a meta-analysis.
Katzka, David A.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | January 21, 2013 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.717961959.793468648 Get It